Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

Wong, 2015, Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States, Gastroenterology, 148, 547, 10.1053/j.gastro.2014.11.039 Goldberg, 2017, Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation, Gastroenterology, 152, 1090, 10.1053/j.gastro.2017.01.003 Younossi, 2011, Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality, Hepatology, 53, 1874, 10.1002/hep.24268 Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease--meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Golabi, 2017, The global epidemiology of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus, Hepatology, 66, 1177A Kwok, 2016, Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study, Gut, 65, 1359, 10.1136/gutjnl-2015-309265 Stepanova, 2013, Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD), Dig Dis Sci, 58, 3017, 10.1007/s10620-013-2743-5 Ong, 2008, Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease, J Hepatol, 49, 608, 10.1016/j.jhep.2008.06.018 Golabi, 2018, Components of metabolic syndrome increase the risk of mortality in non-alcoholic fatty liver disease (NAFLD), Medicine (Baltimore), 97, 10.1097/MD.0000000000010214 Massarweh, 2017, Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Cancer Control, 24, 1, 10.1177/1073274817729245 Younossi, 2015, Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009, Hepatology, 62, 1723, 10.1002/hep.28123 Kim, 2018, Association between non-alcoholic fatty liver disease and cancer incidence rate, J Hepatol, 68, 140, 10.1016/j.jhep.2017.09.012 Dyson, 2014, Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team, J Hepatol, 60, 110, 10.1016/j.jhep.2013.08.011 Pais, 2017, Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period, Aliment Pharmacol Ther, 46, 856, 10.1111/apt.14261 Wong, 2014, Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S, Hepatology, 59, 2188, 10.1002/hep.26986 Cholankeril, 2017, Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes, Dig Dis Sci, 62, 2915, 10.1007/s10620-017-4684-x Parikh, 2017, Projected increase in obesity and non-alcoholic steatohepatitis-related liver transplantation waitlist additions in the United States, Hepatology Cholankeril, 2017, Rising rates of hepatocellular carcinoma leading to liver transplantation in baby boomer generation with chronic hepatitis C, alcohol liver disease, and nonalcoholic steatohepatitis-related liver disease, Diseases, 5, 4, 10.3390/diseases5040020 Flemming, 2017, Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy, Hepatology, 65, 804, 10.1002/hep.28923 Doycheva, 2018, Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in young adults in the United States, J Clin Gastroenterol, 52, 339, 10.1097/MCG.0000000000000925 Younossi, 2018, Current and future therapeutic regimens for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), Hepatology, 68, 361, 10.1002/hep.29724 Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367 Younossi, 2018, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038/nrgastro.2017.109 Thuluvath, 2018, Is cryptogenic cirrhosis different from NASH cirrhosis?, J Hepatol, 68, 519, 10.1016/j.jhep.2017.11.018 Ong, 2001, Cryptogenic cirrhosis and post-transplantation nonalcoholic fatty liver disease, Liver Transpl, 7, 797, 10.1053/jlts.2001.24644 Yalamanchili, 2010, Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease, Liver Transpl, 16, 431, 10.1002/lt.22004 Younossi, 2017, Liver transplantation (LT) for cryptogenic cirrhosis (CC) and non-alcoholic steatohepatitis (NASH) cirrhosis: twenty-two years data from the Scientific Registry of Transplant Recipients (SRTR), Hepatology, 66, 899A Caldwell, 2018, Cryptogenic vs. NASH-cirrhosis: the rose exists well before its name, J Hepatol, 68, 391, 10.1016/j.jhep.2017.12.006 El-Serag, 2014, Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?, Hepatology, 60, 1767, 10.1002/hep.27222 Davila, 2005, Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study, Gut, 54, 533, 10.1136/gut.2004.052167 Kim, 2017, MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma, JAMA Oncol, 3, 456, 10.1001/jamaoncol.2016.3147 Bertot, 2017, Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma, Hepatol Commun, 1, 53, 10.1002/hep4.1018 Sorensen, 2003, Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study, J Clin Gastroenterol, 36, 356, 10.1097/00004836-200304000-00015